REGULATORY

Govt’s Draft Policy Blueprint Prods Continued Debates on Pricing Reform Proposals; Expanded HTA Use, Handling of PMP-Granted Comparators and More

June 12, 2019
The Japanese government on June 11 unveiled a draft paper for this year’s so-called “honebuto” economic and fiscal policy blueprint, calling for discussions on a series of reform plans including a broader application of cost-effectiveness assessments (CEAs), and the removal…

To read the full story

Related Article

REGULATORY

By Reiji Anasako

Riding on the back of an improved regulatory environment in China, major Japanese drug makers are moving to expand their businesses in the world’s second largest pharma market. Companies are pumping up their new drug pipelines, while forging solid sales…

By Reiji Anasako

The female manager ratio at foreign drug makers in Japan has been on the steady rise since the enforcement in April 2016 of the Act on Promotion of Women’s Participation and Career Advancement in the Workplace. Women now account for…

By Yoshinori Sagehashi

As Japan heralds the new imperial era of Reiwa, Eisai CEO Haruo Naito sat with Jiho to look back on…

By Takashi Ebisawa and Tatsuya Otsuka

Japan’s generic market is hitting a plateau soon. Incentive measures rolled out by the government since 2002 have driven its…

By Yoshinori Sagehashi

Some seven years in the making, Japan’s Ministry of Health, Labor and Welfare (MHLW) finally rolled out a cost-effectiveness assessment…

By Takashi Ebisawa

Manufacturers of regenerative medicine-based products are beginning to differentiate themselves from competitors based not only on efficacy but also on the reduction of burdens on medical institutions where their therapies are provided.The procedures required for administering regenerative medicine products are…

Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…

By Philip Carrigan

Earlier this year, I attended a conference discussing the trends of Japan’s pharmaceutical industry. The objective of the conference was to determine what Japanese pharmaceutical companies were doing, and what they could be doing, to make themselves more competitive on…